Analysis of U.S. Patent 10,736,896: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 10,736,896?
U.S. Patent 10,736,896, titled "Methods of Treating Cancer with a KRAS G12C Inhibitor," is assigned to Amgen Inc. and was granted on August 11, 2020. The patent covers compounds, methods of use, and compositions related to KRAS G12C inhibitors designed to treat various cancers.
The patent primarily claims:
- Small molecule inhibitors that selectively target the KRAS G12C mutation.
- Pharmaceutical compositions containing these inhibitors.
- Methods of administering the inhibitors for treating cancers such as non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer.
- Methods for producing these inhibitors.
The scope is centered on specific chemical structures with particular substituents optimized for KRAS G12C binding. The claims encompass both the compounds themselves and their medical applications.
How Are the Claims Structured?
Independent Claims
The patent contains multiple independent claims, notably:
- Claim 1: A chemical compound defined by a core structure with specified substituents, where the compound selectively inhibits KRAS G12C.
- Claim 12: A pharmaceutical composition comprising the compound of claim 1 with a pharmaceutically acceptable carrier.
- Claim 18: A method of treating a KRAS G12C mutant cancer in a subject by administering an effective amount of the compound.
The chemical claim (Claim 1) defines the invention broadly, establishing core chemical structures with variable groups within certain parameters. The method claims (Claims 18+) specify therapeutic applications.
Dependent Claims
Dependent claims narrow the scope, including specific substituents, dosage forms, or treatment regimens. Examples include:
- Variations in chemical substituents that affect binding affinity.
- Specific dosage ranges for treating cancer.
- Use of the compounds in combination with other therapies.
Claim Limitations
Claims are limited to compounds with certain stereochemistry, specific substituents, and binding properties. They do not extend to all KRAS G12C inhibitors but rather to those falling within the defined chemical space.
What is the Patent Landscape?
Patent Family and Priority
The patent family includes families filed in multiple jurisdictions, such as Europe, China, and Canada. Its priority date is October 4, 2018, providing a robust window of exclusivity through at least 2038, assuming no patent term adjustments or extensions.
Competitors and Surrounding Art
Key competitors include Mirati Therapeutics (KRAZATI), AstraZeneca (AZD4621), and others developing KRAS inhibitors, notably sotorasib (AMG 510). Patent filings from these companies often focus on:
- Different chemical scaffolds targeting KRAS G12C.
- Combination therapies involving KRAS inhibitors.
- Alternative methods of inhibiting KRAS signaling.
Patent landscapes feature dense clusters around KRAS G12C structures, with overlapping claims on covalent inhibitors, allosteric modulators, and combination therapies.
Litigation and Patent Thickets
No publicly available litigation records indicate active disputes specifically involving Patent 10,736,896 as of now. However, the patent faces potential challenges from third parties due to overlapping claims with other KRAS G12C inhibitors.
Market and Development Status
The patent's claims underpin Amgen's drug development pipeline, notably its KRAS G12C inhibitors. It provides patent protection for compounds used in clinical trials and those already approved for clinical applications.
Summary of Key Elements
| Aspect |
Details |
| Patent Number |
10,736,896 |
| Filing Date |
October 4, 2018 |
| Issue Date |
August 11, 2020 |
| Assignee |
Amgen Inc. |
| Focus |
KRAS G12C inhibitors; cancer treatment |
| Primary Claims |
Chemical compounds, pharmaceutical compositions, therapeutic methods |
| Patent Family Jurisdictions |
US, Europe, China, Canada |
| Lifespan |
Expiration before 2038 (plus possible extensions) |
| Competitors |
Mirati, AstraZeneca, others |
| Litigation |
None reported |
Why Does the Patent Matter?
This patent secures Amgen's rights over a broad class of KRAS G12C inhibitors, a critical area in oncology. It provides exclusivity for the compounds and methods specified, impacting downstream innovation, licensing, and potential generic entry.
Key Takeaways
- The patent claims chemically defined compounds, compositions, and methods targeting KRAS G12C mutations.
- The chemical scope is broad but specifically limited to certain substituents and stereochemistry.
- The patent landscape is competitive, with dense overlapping claims around covalent KRAS inhibitors.
- The patent family extends internationally, providing global protection, with expiration expected around 2038.
- The patent is integral to Amgen's legal rights to commercialize KRAS G12C-targeted therapies.
FAQs
1. Does U.S. Patent 10,736,896 cover all KRAS G12C inhibitors?
No. It claims specific chemical structures with particular substitutions, not all inhibitors targeting KRAS G12C.
2. What is the patent’s coverage duration?
Filed in 2018, it is set to expire around 2038, subject to patent term adjustments and extensions.
3. Are there similar patents from competitors?
Yes, companies like Mirati and AstraZeneca have filed related patents covering different scaffolds and methods.
4. Can Amgen extend protection via patent term extension?
Potentially, if regulatory delays or other factors justify it, but specifics are not publicly confirmed.
5. How does this patent influence product development?
It provides Amgen exclusive rights to develop and market their KRAS G12C inhibitors based on claimed compounds, limiting competitors’ ability to commercialize similar molecules.
References
- U.S. Patent and Trademark Office. (2020). U.S. Patent 10,736,896.
- WO Patent Application. (2018). Family patent filing priority document.
- Amgen Inc. Press Release. (2020). Announcing progress on KRAS G12C inhibitors.
- PatentScope. (2023). Patent landscape analysis for KRAS inhibitors.
- GlobalData. (2023). Oncology drug pipeline analysis.
